Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547196 · ClinicalTrials.gov registry record · NA
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
A NA study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00547196 is a NA study that has completed, run by City of Hope Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00547196, a NA study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This clinical trial is studying how well four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant work in treating patients with relapsed or refractory hematologic cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Fludarabine phosphate
- DRUG Cyclosporine
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-08-16 |
| Est. Completion | 2024-05-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547196
The ClinicalTrials.gov registry entry for NCT00547196 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00547196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547196 about?
NCT00547196 is a clinical study titled "AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders". RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a donor are infused i...
What is the current status of trial NCT00547196?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2005-08-16. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT00547196?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Fludarabine phosphate (DRUG), Cyclosporine (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00547196?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.